# INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

> **NCT07341958** · NA · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 242 (estimated)

## Conditions studied

- Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)

## Interventions

- **DRUG:** Tafolecimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07341958
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-08-30
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07341958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07341958, "INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07341958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*